title: Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
abstract: BACKGROUND
  The objective of this study was to analyze the impact of visceral metastases in castration-resistant prostate cancer (CRPC) treated with abiraterone.
  
  
  METHODS
  All CRPC patients received abiraterone 1000 mg daily plus prednisone 10 mg orally daily. Liver and lung metastases were considered as visceral metastases.
  
  
  RESULTS
  Of 265 CRPC patients, 49 had visceral metastases. Results on progression-free survival were not significantly different in patients with or without visceral metastases. Conversely, the median overall survival between the two groups was 12.4 and 18.5 months (p = 0.01), respectively, and median overall survival of patients with liver-only disease versus other sites was 10.5 versus 18.5 months (p = 0.006), respectively.
  
  
  CONCLUSIONS
  Visceral disease appears to be an important predictor of clinical outcome in CRPC patients treated with abiraterone.
authors.affiliation: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
authors.forename: Vincenza
authors.initials: V
authors.lastname: Conteduca
authors.affiliation: Santa Chiara Hospital, Trento, Italy.
authors.forename: Orazio
authors.initials: O
authors.lastname: Caffo
authors.affiliation: National Cancer Center CRO, Aviano, Italy.
authors.forename: Lucia
authors.initials: L
authors.lastname: Fratino
authors.affiliation: Santa Maria Degli Angeli General Hospital, Pordenone, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Lo Re
authors.affiliation: Medical Oncology Unit I, Department of Clinical & Experimental Oncology Istituto Oncologico Veneto IOV, IRCCS, Padova, Italy.
authors.forename: Umberto
authors.initials: U
authors.lastname: Basso
authors.affiliation: S Vincenzo Hospital, Taormina, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: D'Angelo
authors.affiliation: Istituti Ospitalieri di Cremona, Cremona, Italy.
authors.forename: Maddalena
authors.initials: M
authors.lastname: Donini
authors.affiliation: Medical Oncology, Azienda Ospedaliera Villa Sofia-Cervello, Palermo, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Verderame
authors.affiliation: Campus Bio-Medico University of Rome, Rome, Italy.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Ratta
authors.affiliation: Oncology Unit I, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Procopio
authors.affiliation: Civil Hospital, Lugo di Romagna, Italy.
authors.forename: Enrico
authors.initials: E
authors.lastname: Campadelli
authors.affiliation: Institut Gustave Roussy, Villejuif, France.
authors.forename: Francesco
authors.initials: F
authors.lastname: Massari
authors.affiliation: University Hospital of Parma, Parma, Italy.
authors.forename: Donatello
authors.initials: D
authors.lastname: Gasparro
authors.affiliation: Dipartimento di Oncologia, Azienda Ospedaliero-Universitaria, Udine, Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: Ermacora
authors.affiliation: Medical Oncology Unit, Piazza OMS, 1, Pope John Paul XXIII Hospital, Bergamo, Italy.
authors.forename: Caterina
authors.initials: C
authors.lastname: Messina
authors.affiliation: Santa Anna Hospital, Como, Italy.
authors.forename: Monica
authors.initials: M
authors.lastname: Giordano
authors.affiliation: Division of Medical Oncology, Università la Sapienza Roma, Rome, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Alesini
authors.affiliation: Medical Oncology Unit I, Department of Clinical & Experimental Oncology Istituto Oncologico Veneto IOV, IRCCS, Padova, Italy.
authors.forename: Vittorina
authors.initials: V
authors.lastname: Zagonel
authors.affiliation: Santa Chiara Hospital, Trento, Italy.
authors.forename: Antonello
authors.initials: A
authors.lastname: Veccia
authors.affiliation: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
authors.forename: Cristian
authors.initials: C
authors.lastname: Lolli
authors.affiliation: Santa Chiara Hospital, Trento, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Maines
authors.affiliation: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
authors.forename: Ugo
authors.initials: U
authors.lastname: De Giorgi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000736:Androstenes / Q000494:pharmacology / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000077143:Docetaxel; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D012189:Retrospective Studies; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D014781:Viscera / Q000473:pathology*
chemical_list: D000736:Androstenes; D018931:Antineoplastic Agents, Hormonal; D043823:Taxoids; D000077143:Docetaxel; C089740:abiraterone
keywords: abiraterone acetate; castration-resistant prostate cancer; liver; survival; visceral metastases